Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based expression system, has announced their participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
The virtual conference is scheduled for March 25-26, 2025, featuring a two-day format with webcast presentations on the first day and one-on-one meetings between Protalix management and pre-qualified investors on the second day. The conference is organized by iAccess Alpha, which hosts virtual investor conferences for recommended companies.
Interested participants are advised to join the call 15 minutes early to complete necessary technical preparations. A recording of the presentation will remain accessible for at least six months through the Events Calendar in the Investors section of Protalix's website.
Protalix BioTherapeutics (NYSE American: PLX), una compagnia biofarmaceutica specializzata in proteine terapeutiche ricombinanti che utilizza il proprio ProCellEx® sistema di espressione a base di cellule vegetali, ha annunciato la sua partecipazione alla prossima iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
La conferenza virtuale è programmata per 25-26 marzo 2025, con un formato di due giorni che prevede presentazioni in webcast il primo giorno e incontri individuali tra il management di Protalix e investitori prequalificati il secondo giorno. La conferenza è organizzata da iAccess Alpha, che ospita conferenze virtuali per investitori per aziende raccomandate.
I partecipanti interessati sono invitati a unirsi alla chiamata 15 minuti prima per completare le necessarie preparazioni tecniche. Una registrazione della presentazione rimarrà accessibile per almeno sei mesi attraverso il Calendario Eventi nella sezione Investitori del sito web di Protalix.
Protalix BioTherapeutics (NYSE American: PLX), una compañía biofarmacéutica especializada en proteínas terapéuticas recombinantes que utiliza su propio sistema de expresión basado en células vegetales ProCellEx®, ha anunciado su participación en la próxima iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
La conferencia virtual está programada para los días 25-26 de marzo de 2025, con un formato de dos días que incluye presentaciones por webcast el primer día y reuniones uno a uno entre la dirección de Protalix y los inversores precalificados el segundo día. La conferencia es organizada por iAccess Alpha, que alberga conferencias virtuales para inversores de empresas recomendadas.
Se aconseja a los participantes interesados unirse a la llamada 15 minutos antes para completar las preparaciones técnicas necesarias. Una grabación de la presentación estará disponible durante al menos seis meses a través del Calendario de Eventos en la sección de Inversores del sitio web de Protalix.
Protalix BioTherapeutics (NYSE American: PLX), 재조합 치료 단백질을 전문으로 하는 생명공학 회사로, 고유한 ProCellEx® 식물 세포 기반 발현 시스템을 사용하고 있습니다. 이 회사는 다가오는 iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025에 참여할 것이라고 발표했습니다.
가상 회의는 2025년 3월 25-26일로 예정되어 있으며, 첫날에는 웹캐스트 발표가 진행되고 둘째 날에는 Protalix 경영진과 사전 자격을 갖춘 투자자 간의 일대일 미팅이 이루어지는 2일 형식으로 진행됩니다. 이 회의는 추천 기업을 위한 가상 투자자 회의를 주최하는 iAccess Alpha에 의해 조직됩니다.
관심 있는 참가자들은 필요한 기술 준비를 완료하기 위해 15분 일찍 전화에 접속할 것을 권장합니다. 발표 녹화는 Protalix 웹사이트의 투자자 섹션의 이벤트 캘린더를 통해 최소 6개월 동안 접근 가능할 것입니다.
Protalix BioTherapeutics (NYSE American: PLX), une entreprise biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes utilisant leur système d'expression à base de cellules végétales ProCellEx®, a annoncé sa participation à la prochaine iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
La conférence virtuelle est prévue pour les 25-26 mars 2025, avec un format de deux jours comprenant des présentations en webcast le premier jour et des réunions individuelles entre la direction de Protalix et des investisseurs préqualifiés le deuxième jour. La conférence est organisée par iAccess Alpha, qui accueille des conférences virtuelles pour investisseurs pour des entreprises recommandées.
Les participants intéressés sont invités à se joindre à l'appel 15 minutes en avance pour compléter les préparatifs techniques nécessaires. Un enregistrement de la présentation restera accessible pendant au moins six mois via le calendrier des événements dans la section Investisseurs du site web de Protalix.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante therapeutische Proteine spezialisiert hat und sein eigenes ProCellEx® pflanzenzellbasiertes Expressionssystem verwendet, hat seine Teilnahme an der bevorstehenden iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025 bekannt gegeben.
Die virtuelle Konferenz ist für den 25.-26. März 2025 angesetzt und bietet ein zweitägiges Format mit Webcast-Präsentationen am ersten Tag und Einzelgesprächen zwischen dem Management von Protalix und vorqualifizierten Investoren am zweiten Tag. Die Konferenz wird von iAccess Alpha organisiert, das virtuelle Investorenkonferenzen für empfohlene Unternehmen veranstaltet.
Interessierte Teilnehmer werden gebeten, 15 Minuten früher anzurufen, um notwendige technische Vorbereitungen zu treffen. Eine Aufzeichnung der Präsentation wird mindestens sechs Monate lang über den Veranstaltungskalender im Investorenbereich der Protalix-Website zugänglich sein.
- None.
- None.
CARMIEL,
iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management and pre-qualified investors on Day 2.
For more information about the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, or to register and schedule a one-on-one meeting with Protalix, please visit the conference website at: https://www.iaccessalpha.com/home.
iAccess Alpha Virtual Best Ideas Spring Conference 2025
Live Presentation | |
Date: | Tuesday, March 25, 2025 |
Time: | 12:00 p.m. Eastern Daylight Time (EDT) |
Company Link: | |
Webcast Link: | |
Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for at least six months on the Events Calendar of the Investors section of Protalix's website, at the above link.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-iaccess-alpha-virtual-best-ideas-spring-conference-2025-302409050.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When is Protalix BioTherapeutics (PLX) presenting at the iAccess Alpha Conference 2025?
What is the format of PLX's participation in the iAccess Alpha Conference 2025?
How long will PLX's iAccess Alpha Conference presentation be available for replay?
What technology does PLX use for protein production?
